Editorial
Copyright ©2011 Baishideng Publishing Group Co.
World J Clin Oncol. Mar 10, 2011; 2(3): 135-149
Published online Mar 10, 2011. doi: 10.5306/wjco.v2.i3.135
Table 2 Antiangiogenic agents in upper gastrointestinal malignancies
DrugMechanism of actionApplicable tumor sites
BevacizumabIntravenous recombinant humanized monoclonal antibody against VEGFGastric
Hepatocellular
Biliary tract
Pancreas
SunitinibOral multitargeted TKI inhibiting VEGFR-1, VEGFR-2, PDGFR-β, c-KIT, FLT3, and RETGastric
Hepatocellular
SorafenibOral multitargeted TKI inhibiting VEGFR-1, VEGFR-2, PDGFR-β, Raf-1, B-Raf, and intracellular serine-threonine kinasesGastric
Hepatocellular
Pancreas